Suivre
Michael L. Miller
Michael L. Miller
SynerG Biopharma Group
Adresse e-mail validée de synergbiopharma.com
Titre
Citée par
Citée par
Année
Antibody–drug conjugates: an emerging concept in cancer therapy
RVJ Chari, ML Miller, WC Widdison
Angewandte Chemie International Edition 53 (15), 3796-3827, 2014
10302014
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
RY Zhao, ML Miller, WC Widdison, RVJ Chari
US Patent 6,716,821, 2004
3572004
Disulfide-linked antibody− maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage
BA Kellogg, L Garrett, Y Kovtun, KC Lai, B Leece, M Miller, G Payne, ...
Bioconjugate chemistry 22 (4), 717-727, 2011
2532011
Benzodiazepine derivatives
W Li, N Fishkin, R Zhao, M Miller, R Chari
US Patent 8,426,402, 2013
1822013
Chemistry and chemical biology of taxane anticancer agents
ML Miller, I Ojima
The Chemical Record 1 (3), 195-211, 2001
1722001
Synthesis and structure-activity relationships of new second-generation taxoids
I Ojima, T Wang, ML Miller, S Lin, CP Borella, X Geng, P Pera, ...
Bioorganic & medicinal chemistry letters 9 (24), 3423-3428, 1999
1371999
Design, synthesis, and biological evaluation of new-generation taxoids
I Ojima, J Chen, L Sun, CP Borella, T Wang, ML Miller, S Lin, X Geng, ...
Journal of medicinal chemistry 51 (11), 3203-3221, 2008
1292008
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
RVJ Chari, ML Miller
US Patent 6,596,757, 2003
1152003
Macrocycle formation by ring-closing metathesis. Application to the syntheses of novel macrocyclic taxoids
I Ojima, S Lin, T Inoue, ML Miller, CP Borella, X Geng, JJ Walsh
Journal of the American Chemical Society 122 (22), 5343-5353, 2000
1132000
Folate receptor–specific antitumor activity of EC131, a folate-maytansinoid conjugate
JA Reddy, E Westrick, HKR Santhapuram, SJ Howard, ML Miller, M Vetzel, ...
Cancer Research 67 (13), 6376-6382, 2007
1122007
A new class of antibody–drug conjugates with potent DNA alkylating activity
ML Miller, NE Fishkin, W Li, KR Whiteman, Y Kovtun, EE Reid, KE Archer, ...
Molecular Cancer Therapeutics 15 (8), 1870-1878, 2016
1072016
Methods of preparation of conjugates
N Fishkin, M Miller, W Li, R Singh
US Patent 9,353,127, 2016
742016
Synthesis of novel C2− C3 ‘N-linked macrocyclic taxoids by means of highly regioselective Heck macrocyclization
X Geng, ML Miller, S Lin, I Ojima
Organic Letters 5 (20), 3733-3736, 2003
652003
Design, synthesis and structure− activity relationships of novel taxane-based multidrug resistance reversal agents
I Ojima, CP Borella, X Wu, PY Bounaud, CF Oderda, M Sturm, ML Miller, ...
Journal of medicinal chemistry 48 (6), 2218-2228, 2005
572005
A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody–drug conjugates (ADCs)
ML Miller, M Shizuka, A Wilhelm, P Salomon, EE Reid, L Lanieri, S Sikka, ...
Molecular Cancer Therapeutics 17 (3), 650-660, 2018
532018
Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery
ML Miller, EE Roller, RY Zhao, BA Leece, O Ab, E Baloglu, ...
Journal of medicinal chemistry 47 (20), 4802-4805, 2004
532004
Cytotoxic benzodiazepine derivatives
W Li, M Miller, N Fishkin, RVJ Chari
US Patent 8,765,740, 2014
522014
Cytotoxic benzodiazepine derivatives
W Li, ML Miller, NE Fishkin, RVJ Chari
US Patent 8,889,669, 2014
512014
Benzodiazepine derivatives
W Li, NE Fishkin, RY Zhao, ML Miller, RVJ Chari
US Patent 8,802,667, 2014
462014
Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers
PL Salomon, EE Reid, KE Archer, L Harris, EK Maloney, AJ Wilhelm, ...
Molecular pharmaceutics 16 (12), 4817-4825, 2019
392019
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20